The fact that lenacapavir will soon be available to patients is a testament to the strength of America's biopharmaceutical ...

The risk for MACEs was higher among patients with HIV infection receiving abacavir- vs tenofovir-based ART regimens.

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...